How much does Knox Pharmaceuticals Limited make?

Knox Pharmaceuticals Limited reported revenue of £37.1m and £3.8m profit in the year to 31 Oct 2025, according to its accounts filed at Companies House.

How many employees does Knox Pharmaceuticals Limited have?

Knox Pharmaceuticals Limited reported an average of 38 employees in the year to 31 Oct 2025.

Is Knox Pharmaceuticals Limited profitable?

Yes — Knox Pharmaceuticals Limited reported a profit of £3.8m in the year to 31 Oct 2025.

Company No. 03047023 · Incorporated 18 Apr 1995

Knox Pharmaceuticals Limited

Registered name: KNOX PHARMACEUTICALS LIMITED

Part of Knox Holdings Limited group

Knox Pharmaceuticals Limited made £37.1m revenue and £3.8m profit in the year to 31 Oct 2025. read from filing text

Knox Pharmaceuticals Limited’s revenue grew 23% to £37.1m in the year to 31 Oct 2025, with £3.8m profit and 38 employees. The company is classified under “wholesale of pharmaceutical goods” and is based in Ripon; we hold 4 years of its filed accounts.

Full P&L filedSection G · Wholesale and retail trade; repair of motor vehiclesSIC 46460Wholesale of pharmaceutical goods

Status: Active
Location: Ripon, Yorkshire and The Humber
Age: 31 yrs · since 1995
Type: Private Limited Company

Part of a group. The filing indicates this company sits within a group structure, so its results may depend on intra-group trading and it may be hard to replicate independently. From the filing: “The parent company of Knox Pharmaceuticals Limited is Knox Holdings Limited, and its registered office is Unit 2 Barugh Way, Barker Business Park, Melmerby, Ripon, North Yorkshire, HG4 5NG.”

Latest accounts · year to 31 Oct 2025

Key figures

Capital-lightDoing more with less

Revenue

£37.1m

Growth ▲22.6%

Profit

£3.8m

Growth ▲21.6%

Profit margin

10.3%

Gross 17.6%

Employees

Change ▼2.6%

Profit / employee

£101k

Revenue/employee £976k

Profitable streak

4yrs

Consecutive profitable years in our data

Badges are automated estimates derived from the filed figures — not statements of fact about the company.

4 filed years

Financial history

Multi-year financials, oldest to newest
Year to	31 Oct 2022	31 Oct 2023	31 Oct 2024	31 Oct 2025
Disclosure	Full P&Lread from filing text	Full P&Lread from filing text	Full P&Lread from filing text	Full P&Lread from filing text
Profit & loss
Revenue (turnover)	£23.2m	£27.2m	£30.3m	£37.1m
Cost of sales	£18.5m	£22.2m	£24.3m	£30.6m
Gross profit	£4.7m	£5m	£5.9m	£6.5m
Operating profit	£4.2m	£3.5m	£4.2m	£5.1m
Profit before tax	£4.2m	£3.5m	£4.2m	£5.1m
Profit after tax	£3.4m	£2.7m	£3.1m	£3.8m
Profit (best available)	£3.4m	£2.7m	£3.1m	£3.8m
Staff costs	£957k	£1.2m	£1.4m	£1.3m
Employees (average)	42	39	39	38
Ratios
Profit margin	14.6%	9.9%	10.4%	10.3%
Gross margin	20.4%	18.3%	19.7%	17.6%
Revenue per employee	£553k	£697k	£776k	£976k
Profit per employee	£80.8k	£69.3k	£80.7k	£101k
Growth (year on year)
Revenue growth	—	▲17.1%	▲11.3%	▲22.6%
Profit growth	—	▼20.3%	▲16.4%	▲21.6%
Headcount growth	—	▼7.1%	0%	▼2.6%
Balance sheet — indirect signals, not revenue
Cash at bank	£1.7m	£2.4m	£1.1m	£2m
Net assets	£5.3m	£6.6m	£6m	£8.6m
Fixed assets	£945k	£1m	£1.1m	£1.2m
Current assets	£7.1m	£8.5m	£8m	£10.9m
Debtors	£3.2m	£4.2m	£4.6m	£5.9m
Deferred income	£60.2k	£66k	£130k	£349k
Source	FullAccounts · bulk data Jul 2024	FullAccounts · bulk data Jul 2024	FullAccounts · bulk data Jul 2025	FullAccounts · bulk data Jul 2026

Derived from the latest filing

How the business works

Profit margin: 10.3%; Profit ÷ revenue.
Gross margin: 17.6%; Gross profit ÷ revenue. High for software and services.
Revenue per employee: £976k; Revenue ÷ average employees.
Profit per employee: £101k; Profit ÷ average employees.
Cash conversion: —; Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
Fixed assets ÷ revenue: 3.3%; Capital intensity. Low = capital-light, cheaper to start.
Deferred income ÷ revenue: 0.9%; Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
Debtors ÷ revenue: 16%; Money owed by customers. Low = customers pay quickly.

Indirect — not revenue

Balance-sheet signals

Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.

Net assets: ▲43%; Now £8.6m
Cash at bank: ▲71%; Now £2m
Headcount: ▼3%; Now 38
Deferred income: ▲167%; Now £349k
Fixed assets: ▲7%; Now £1.2m

Deferred income is reported together with accruals in this filing (“accruals and deferred income”), so it is an approximate signal only.

Corporate ownership

Group structure

Ownership chain

Knox Holdings Limitedultimate parent75–100%
Knox Pharmaceuticals Limitedthis company

Bands show the share of ownership each company holds in the one below it.

From the Persons with Significant Control register (corporate controllers only).

Same industry, similar size

Similar profitable businesses

Industry benchmarks →

Sources

Companies House profile Filing history & original accounts

Latest figures from FullAccounts for the year to 31 Oct 2025 (profit £3.8m), from the Companies House accounts bulk data published Jul 2026. Spotted an error? Request a correction.

Updated from Companies House on 24 Oct 2026

Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.